Specific warning signs that require prompt medical assessment include: Symptoms suggesting nocturnal hypoglycaemia (night sweats, palpitations, confusion upon waking) Signs of pancreatitis (severe, persistent abdominal pain that may radiate to the back, accompanied by vomiting) [16] [1] Other severe gastrointestinal complications (persistent vomiting, signs of dehydration) Mental health concerns such as significant anxiety, depression, or mood changes Patients with pre-existing sleep disorders, such as sleep apnoea or insomnia, should inform their healthcare provider before starting Wegovy, as weight loss may improve these conditions but the medication could theoretically interact with existing sleep problems
There is growing consensus regarding their pathophysiology and management, but more work is needed to elucidate the relationships between irAEs and treatment outcomes, specific biomarkers that clinch an irAE diagnosis, the impact of tailored immunosuppression on ICI outcomes, and the management of steroid-refractory irAEs
Safety and Considerations Both AOD 9604 and tirzepatide have shown good safety profiles in studies
Any concerns about dosage or symptoms should be discussed with a qualified healthcare professional
